Latest Adeno-associated virus Stories
Tag-team Approach Breaks the Size Barrier for Gene Therapy.
Researchers at Nationwide Children's Hospital and Johns Hopkins University have discovered that delivering a small molecule that is highly expressed in normal tissues but lost in diseased cells can result in tumor suppression.
A new study suggests that delivering small RNAs, known as microRNAs, to cancer cells could help to stop the disease in its tracks. microRNAs control gene expression and are commonly lost in cancerous tumors.
Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients; Phase 2 Study Currently Enrolling in 17 Leading U.S.
Researchers from the University of California, Berkeley, and the University of Iowa have turned a relatively benign virus into a highly infectious form that is ideal as a carrier for gene therapy.
Targeted Genetics Corporation (NASDAQ: TGEN) will report its third quarter 2008 financial results after the close of the financial markets on Wednesday, November 5, 2008.
Targeted Genetics Corporation (NASDAQ: TGEN) announced positive results of its now completed Phase 1/2 clinical study with the last subject having finished the protocol-required follow-up.
AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson's disease.
Neurologix, a biotechnology company engaged in the development of gene therapies for the brain and central nervous system, and Aegera Therapeutics, a private clinical stage company focused on oncology and neuropathic pain, have executed an exclusive license agreement.
- totally perplexed and mixed up.